Lionheart Health has announced a strategic partnership with Rejuvant as part of its participation in the XPRIZE Healthspan Semi-Finals, where the company was selected as a top 40 semi-finalist out of more than 600 entries in spring 2025. Under this collaboration, Rejuvant's patented, sustained-release Calcium alpha-ketoglutarate (CaAKG) supplement has been designated a mandatory core component of the Lionheart KLOTHO-UP™ Study and the broader Lionheart Klotho Wellness Program, both central to Lionheart's XPRIZE Healthspan initiative.
The partnership integrates Rejuvant's CaAKG supplementation—associated with peer-reviewed research demonstrating improvements in biological age markers—within Lionheart's multi-modal healthspan optimization framework designed to evaluate coordinated improvements across muscle, metabolic, immune, cardiovascular, and brain health domains. This integrated approach reflects Lionheart's belief that meaningful healthspan extension requires both lifestyle optimization and advanced biological technologies working in concert.
In addition to Rejuvant CaAKG, all study participants receive SNiP Nutrition™ personalized supplements customized based on genetic and biomarker profiles, targeted Klotho-focused supplementation, and Lionheart Health's BodStim™ bioelectric exercise platform delivering Klotho- and follistatin-elevating electrical muscle stimulation-enhanced exercise sessions. The comprehensive testing protocol includes a 461-biomarker blood panel, AI-enhanced full-body MRI, muscle health assessments, gut health and microbiome evaluation, and brain health testing with cognition, memory, and mood metrics, enabling objective tracking of functional healthspan changes over time.
A spokesperson for Lionheart Health stated that Rejuvant's CaAKG platform represents one of the most rigorously studied nutritional interventions in the biological aging space, anchoring their program in validated metabolic biology while layering in advanced bioelectric, Klotho-focused, and personalized technologies. A representative from Rejuvant added that this collaboration allows CaAKG supplementation to be evaluated within one of the most comprehensive, biomarker-driven healthspan programs ever assembled. More information about the program is available at https://lionheartlongevity.com/treatment/klotho-wellness-program/.
For business and technology leaders, this partnership represents a significant development in the longevity technology sector, demonstrating how validated biological interventions can be integrated with advanced diagnostic and therapeutic technologies to create comprehensive healthspan solutions. The collaboration between a regenerative health technology company and a longevity biotechnology firm highlights the growing convergence of different scientific approaches in the aging research field, potentially accelerating the development of practical interventions that could impact workforce productivity, healthcare costs, and quality of life across aging populations.
The XPRIZE Healthspan competition provides a structured framework for evaluating such integrated approaches, with Lionheart's multi-modal strategy offering insights into how different interventions might work synergistically rather than in isolation. The mandatory inclusion of Rejuvant's CaAKG supplement—backed by peer-reviewed research—within this broader technological platform suggests a maturation of the longevity industry toward evidence-based combinations of interventions rather than single-solution approaches.
